Wednesday, 29 August 2012

Beta interferon and azathioprine


OBJECTIVES: To evaluate safety and efficacy of add-on low-dose azathioprine or interferon (IFN)-beta in MSers with active MS despite monotherapy.
 
METHODS: This retrospective observational study evaluated 5-year data from 85 MSers with active MS despite monotherapy with either IFN-beta or azathioprine, who received add-on azathioprine or IFN-beta, respectively. In a subgroup of 23 patients, 10-year data were analysed. Clinical (relapse frequency, disability) and laboratory effects were compared preceding and following the addition of second drug and between the two treatment regimens. Potential serious adverse events were evaluated.
 
RESULTS: The add-on treatment triggered a drop in annualised relapse rate by approximately 1.5 points sustained over 5 and 10 years. No effect on disability was observed. Simultaneously, white blood cell and lymphocyte counts decreased, being below the physiological levels in 8% and 13% of patients at each time point, respectively. The drop in relapse rate was independent from the dosage of azathioprine or changes in lymphocyte count. Comparison between the two treatment regimens showed that, with the exception of lymphocyte count, these effects were triggered by the add-on of interferon but not azathioprine. The combination therapy was well tolerated; however, after 5 years on treatment a moderately increased incidence of cancer was observed.
 
CONCLUSIONS: IFN-beta as add-on to azathioprine decreases relapse activity in active MS. In contrast, azathioprine add-on in patients with suboptimal response to IFN-beta does not improve the control over the disease activity.
How azathioprine works!

"This is a retrospective study that is uncontrolled and observational. This is why we do randomised, double-blind, placebo-controlled trials that are adequately powered. What does the statement "moderately increased incidence of cancer was observed" mean? Compared to what? The effectiveness of azathioprine in MS is unproven; it is a pity as it a cheap drug and relatively easy to use. If we knew then, what we know now, we would have done properly powered azathioprine studies and could have saved the NHS millions of pounds. May be in another lifetime, or parallel universe, azathioprine will get showing."

No comments:

Post a Comment

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.